Half Year 2025 Gubra A/S Earnings Call Transcript
Key Points
- Gubra AS (FRA:PI3) reported the most successful half-year in its history in terms of revenue, driven by a significant deal worth USD 2.2 billion.
- The company paid out a substantial dividend of DKK1 billion, showcasing its strong financial position.
- Gubra AS has a robust pipeline with several promising programs, including the GUBamy and UCN2 programs, which show potential for significant advancements in weight management and obesity treatment.
- The company has a strong reputation in the CRO service business, serving 16 out of the top 20 pharma companies globally.
- Gubra AS is expanding its service offerings by adding women's health to its CRO business, targeting an underserved area with potential for growth.
- The CRO business experienced a slight decline in revenue for the first half of 2025 compared to the previous year, attributed to challenges in the US market.
- There is macroeconomic uncertainty in the US, affecting funding opportunities for smaller biotech companies, which impacts Gubra's CRO business.
- The company revised its revenue outlook for the CRO business to be slightly below the previous year's record levels.
- Gubra AS lowered its EBITDA margin guidance to around 20%, down from the previous assumption of 25% to 31%, due to investments in new areas like women's health.
- The transition of the CEO role from Henrik Blou to Markus Rohrwild may introduce uncertainties in leadership continuity.
Thank you for standing by. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to the Gubra Q2 2025 earnings release.
(Operator Instructions)
I would not like to turn the call over to Henrik Blou, CEO. Please go ahead.
Thank you very much. It's a pleasure for us to present the highlights from 2025 to you today. So, with me here, I have Louise Dalboge Gubra's CSO and Kristian Borbos Gubra's CFO.
At Google, we are experts in metabolic diseases and other diseases related to the human metabolism.
We have a hybrid business model where the core research engine we built, we use it to sell research services as a CRO.
And also to advance our own internal pipeline programs towards a future partnerships. And we have a long history of growth. Today we are approximately 275 colleagues here at Gubra and in the service business, we are servicing 16 out of 20 pharma companies. In the world, so we have a very strong reputation
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
